JNM Podcast

Nuclear medicine is uniquely positioned at the intersection of diagnostics and therapeutics, so should it remain housed with imaging modalities, or stand alone as an independent specialty? Those against independence cite its commonalities with other specialties and the necessity of integrating nuclear medicine into more parts of patient care. Proponents cite the field's specialized workforce, as well as clinical and operational needs, adding that nuclear medicine faces challenges not served by other departments. Are we better within another department, or should we fly solo? Host Ken Herrmann, MD, PhD., is joined by Ora Israel, MD, Martin Pomper, MD, PhD, and Johannes Czernin, MD, to debate the pros and cons of independence. Spoiler alert: every expert on this JNM panel has a different opinion. What's yours?  Listen now!Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/

A popular saying in the nuclear medicine field is that our work spans "from bench to bedside." But the path to get there isn't always clear. Even though there are constant breakthroughs in research and development, the cutting-edge treatments offered by nuclear medicine don't always make it to the patients who need it the most. Barriers within existing healthcare infrastructure, like the workforce pipeline, procedure implementation, and regulatory hurdles all contribute to gaps in patient access to radioligand therapy. But our panel of experts has solutions. In this episode of The JNM Podcast, Ken Hermann, MD, is joined by Vesna Gershan, PhD, Andrei Iagaru, MD, FACNM, FSNMMI, and Uwe Holzwarth, PhD, as they discuss how to increase patient access to nuclear medicine care.This episode is sponsored by Novartis: https://www.novartis.com/

Before we pop the champagne and count down to 2026, let’s take one last look back at 2025 through our favorite moments in nuclear medicine. Join host Ken Herrmann and his group of “JNM All-Stars:” Tom A. Hope, MD, Irene Buvat, PhD, and Jason S. Lewis, PhD, as they reminisce on their favorite parts of 2025. Tune in before the ball drops!

Data tells us that nuclear medicine has made extraordinary strides in curing prostate cancer, especially with the use of PSMA PET. But how are we reporting on PSMA, and how can this data be standardized globally? SPARC could be the answer! SPARC stands for "Standardized PSMA Reporting Criteria," and it's been initiated because of the widespread use and success of PSMA PET. These guidelines were developed by asking the end-users of PSMA PET reporting what they need and working backwards from there. So what went into this process, and what guidelines may we see going forward? On this episode of The JNM Podcast, host Ken Herrmann talks with Louise Emmett, MD, Anders Bjartell, MD, PhD, FEBU, Michael Morris, MD, and Jochen Walz, MD, about the reporting guidelines that SPARC outlines for nuclear medicine physicians.This episode is sponsored by the European Association of Urology: https://uroweb.org 

Being able to personalize a patient's treatment is one of the cornerstones of nuclear medicine, but how are we able to do that? PET-Guided radiotherapy is one answer. In addition to staging and defining a disease, PET imaging can also give providers important information about what's going on in the body while a patient is undergoing their treatment regimen. PET can be used to adjust radiotherapy based on changes in the body and disease progression — whether higher doses are needed in areas with more aggressive cancer, or lower, but still effective, doses can be administered to ensure the minimal amount of toxicity to a patient. Join us for this episode of the JNM Podcast as host Ken Herrmann talks with radiotherapy experts Wolfgang Weber and Nancy Lee. Listen on YouTube or wherever you stream podcasts. This episode is sponsored by GE Healthcare: https://www.gehealthcare.com/products/molecular-imaging

Biomarkers: what are they and how are they useful in the diagnosis and treatment of prostate cancer? On this episode of the JNM Podcast, our panel of experts explores what they call a "liquid biopsy:" using biomarkers shed by cancer cells into the bloodstream to gain vital insights about the disease and its progression, identify candidates who would benefit from certain therapies, and monitor the effectiveness of treatments. Listen now to learn more about the clinical use of biomarkers. Our host Ken Herrmann, MD, is joined by Jake Berchuck, MD, Alexander Wyatt, PhD, and Rana McKay, MD.This episode is sponsored by Precede Biosciences: https://www.precede.bio/

Is it really happening? Astatine-211 is a promising new radionuclide being further developed and researched for the treatment of cancer. It is a short half-life alpha-emitter that's attracting more interest from the nuclear medicine community as investors take notice of its potential and production capacity improves. So where will 211At be by 2030? And is this a radionuclide that could show up in a clinical setting in the near future? Join host Ken Herrmann, MD with guests Brenda Sandmaier, MD, Tadashi Watabe, MD, and Ferid Haddad PhD, as they discuss the future of this isotope.This episode is sponsored by IBA Radiopharma Solutions (https://www.iba-radiopharmasolutions.com/) and Accelerate.eu (https://ihi-accelerate.eu/)

In this live episode of The JNM Podcast, Johannes Czernin interviews Anna Karmann to talk about the various career trajectories available in nuclear medicine.

The JNM Podcast is back and live from New Orleans. Guests David Mankoff, Hossein Jadvar, and Todd Peterson answer the question: "Can society-based journals compete with corporate-based publications?"

You love the column, now hear it in person! Throughout the meeting, JNM Editor in Chief Johannes Czernin will host Discussions with Leaders to talk about the most important and exciting topics in nuclear medicine. First up is Richard Wahl, MD.

Standardized uptake values (SUV) measure a patient's response to nuclear medicine therapy. But what other markers of success are there, and do these markers and the interpretation of them vary depending on the disease being imaged? Sally Barrington, MD, works specifically on lymphoma and shares her expertise on what markers of success and criteria are critical to her in understanding patients' responses to treatment.  Joining her, along with our host Ken Herrmann, MD, are Louise Emmett, MD, and Irene Buvat, PhD. The panel also discusses the role of AI tools in analyzing risk and response assessment in lymphoma. Tune in now!Below are resources provided by Dr. Barrington: Tool to measure the international metabolic prognostic index 'IMPI':https://petralymphoma.org/impi/Benchmark dataset for MTV measurement:   https://zenodo.org/records/11409717For more JNM articles on this topic, see below:Methodology for MTV described in DOI: https://jnm.snmjournals.org/content/early/2020/07/16/jnumed.119.238923Is 18F-FDG Metabolic Tumor Volume in Lymphoma Really Happening? https://doi.org/10.2967/jnumed.123.267022Deep learning enables TMTV estimation  https://doi.org/10.2967/jnumed.120.242412This episode is sponsored by SOFIE Biosciences: https://sofie.com/

Is PSMA becoming so regularly used that it's...boring? Not according to this lively discussion. Join us for episode 9 of the JNM Podcast, where host Ken Herrmann discusses the state of PSMA PET with experts Thomas Hope, Oliver Sartor, and Wolfgang Fendler. The panel talks about PSMA PET in clinical trials vs. real-life disease management, appropriate use criteria and its evolution, and patient and treatment data. Plus, what's next for PSMA as it matures into adulthood? Tune in to find out!Thanks to Sofie Biosciences for sponsoring this episode. https://sofie.com/

The JNM Podcast is back in 2025! Join Ken Herrmann, MD, and co-moderator Frank Bengel, MD, for an episode on cardiovascular perfusion imaging. In the U.S., SPECT imaging makes up five to six million studies per year. But PET studies make up just 2.2 million, and only 7%, or 150,000 of those, are cardiac PET imaging. But that may be about to change. The FDA has recently approved Flurpiridaz F-18, which may make cardiac imaging more accessible to patients across the country. Here to discuss the utility of the F-18 label and the future of myocardial perfusion imaging are Jamshid Maddahi, MD, FACC, FASNC, and Sharmila Dorbala, MD, MPH.Thanks to GE Healthcare for sponsoring this episode! https://www.gehealthcare.com/products/molecular-imaging-agents/flyrcado

Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune in now!Thanks to Sofie Biosciences for sponsoring this episode! https://sofie.com/

Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients.Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/

Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it.Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany). Panelists: Andrei Iagaru, MD (Stanford University Medical Center, Stanford, California), Leonhard Schaetz (Novartis, Basel, Switzerland), and Désirée Deandreis, MD (Gustave Roussy, Villejuif, France).Sponsored by SOFIE Biosciences (https://sofie.com) 

The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM Podcast from The Journal of Nuclear Medicine.Moderators: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany) and Heiko Schoder, MD, MBA (Memorial Sloan Kettering Cancer Center)Panelist: Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center)Thank you to SOFIE Biosciences for sponsoring this episode. https://sofie.com/

This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD, leads this intercontinental panel in a discussion about other radionuclides and their pros and cons. He's joined by David Bauer, PhD, from Memorial Sloan Kettering Cancer Center, Jane Sosabowski, BSc, MSc, PhD, from Queen Mary, University of London, and Nick Fletcher, PhD, from the University of Queensland, Australia.

The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches.Panel: • Ken Herrmann, MD, MBA (Universitätsmedizin, Essen, Germany)• Henryk Barthel, MD, PhD (Leipzig University)• Gil Rabinovici, MD (University of California - San Francisco)• Victor Villemagne, MD (University of Pittsburgh)

The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss challenges, and predict the pathway to clinical success. #JNuclMed #NuclearMedicine #FAPI #Theranostics